每经AI快讯，普莱柯1月20日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利润为 1.76亿元~1.95亿元，与上年同期相比，增加8319.35万元~1.02亿元，同比上升89.64%~110.11%。业绩变 动主要原因是，报告期，禽腺病毒系列联苗等新产品上市为公司贡献了新的业绩增长点，宠物板块通过 持续发力渠道搭建和品牌打造进而取得了快速发展。2025年，面对行业竞争加剧、价格承压以及下游养 殖行情波动等不利因素，公司聚焦营销体系变革，加强销售费用管控，同时优化生产工艺和采购管理， 进一步降低生产成本，整体展现了较强的经营韧性，实现了高质量、高效益发展的经营目标。 （记者 曾健辉） 每经头条（nbdtoutiao）——"一周干完一年的活"，一款AI编程工具让硅谷程序员集体"上瘾"！科技公 司CEO：一辈子钻研的技能被它一次性解决，让人兴奋又恐惧 ...

人民财讯1月20日电，普莱柯（603566）1月20日公告，预计2025年年度实现归属于母公司所有者的净利 润为1.76亿元到1.95亿元，同比上升89.64%到110.11%。报告期，禽腺病毒系列联苗等新产品上市为公 司贡献了新的业绩增长点，宠物板块通过持续发力渠道搭建和品牌打造进而取得了快速发展。 ...

普莱柯（603566）(603566.SH)披露2025年年度业绩预告，公司预计2025年年度实现归属于母公司所有 者的净利润为1.76亿元到1.95亿元，同比上升89.64%到110.11%;实现归属于母公司所有者的扣除非经常 性损益的净利润为1.37亿元到1.53亿元，同比上升70.19%到90.07%。 报告期，禽腺病毒系列联苗等新产品上市为公司贡献了新的业绩增长点，宠物板块通过持续发力渠道搭 建和品牌打造进而取得了快速发展。 ...

智通财经APP讯，普莱柯(603566.SH)披露2025年年度业绩预告，公司预计2025年年度实现归属于母公 司所有者的净利润为1.76亿元到1.95亿元，同比上升89.64%到110.11%;实现归属于母公司所有者的扣除 非经常性损益的净利润为1.37亿元到1.53亿元，同比上升70.19%到90.07%。 报告期，禽腺病毒系列联苗等新产品上市为公司贡献了新的业绩增长点，宠物板块通过持续发力渠道搭 建和品牌打造进而取得了快速发展。 ...

格隆汇1月20日丨普莱柯(603566.SH)公布，经公司财务部门初步测算，预计2025年年度实现归属于母公 司所有者的净利润为17,600.00万元到19,500.00万元，同比上升89.64%到110.11%。预计2025年年度实现 归属于母公司所有者的扣除非经常性损益的净利润为13,700.00万元到15,300.00万元，同比上升70.19% 到90.07%。 报告期，禽腺病毒系列联苗等新产品上市为公司贡献了新的业绩增长点，宠物板块通过持续发力渠道搭 建和品牌打造进而取得了快速发展。2025年，面对行业竞争加剧、价格承压以及下游养殖行情波动等不 利因素，公司聚焦营销体系变革，加强销售费用管控，同时优化生产工艺和采购管理，进一步降低生产 成本，整体展现了较强的经营韧性，实现了高质量、高效益发展的经营目标。 ...

普莱柯公告称，预计2025年年度实现归属于母公司所有者的净利润1.76亿元到1.95亿元，同比上升 89.64%到110.11%；扣非净利润1.37亿元到1.53亿元，同比上升70.19%到90.07%。上年同期，公司归母 净利润9280.65万元，扣非净利润8049.70万元。业绩预增主要因禽腺病毒系列联苗等新产品上市，宠物 板块发展良好，且公司聚焦营销变革、降本增效。本次业绩预告为初步测算数据，未经审计。 ...

据天眼查APP显示，武汉回盛生物科技股份有限公司成立于2002年01月25日，注册资本20233.2557万人 民币。 数据宝统计，截至14:00，回盛生物成交额10.01亿元，创2025年5月23日以来新高。最新股价上涨 10.80%，换手率16.28%。上一交易日该股全天成交额为9.35亿元。 （文章来源：证券时报网） ...

Group 1: Business Performance and Growth - The company's core products continue to drive growth, with the vaccine business accounting for over 50% of the overall business, becoming a key driver for product structure upgrade [2] - In 2025, the company achieved significant progress in R&D, obtaining the world's first clinical approval for an mRNA vaccine for food animals, and established a GMP mRNA vaccine production line [2] - The company has optimized internal management, resulting in a net profit growth rate significantly higher than revenue growth, showcasing operational resilience [2] Group 2: Market Expansion and Future Plans - In 2025, the company completed multiple overseas product registrations, laying the foundation for future large-scale exports [3] - Future global expansion will focus on new product registrations, acquisitions of overseas companies, and increased R&D investment to gradually enhance the export share of formulations and vaccines [3] - The company aims to deepen its market presence in the pet sector and synthetic biology, contributing to performance growth [2] Group 3: Supply Chain and Coverage - As of 2025, the company's supply chain covers approximately 7,000 pet hospitals and 4,000 pet stores, achieving a national coverage rate of about 35% [3] - Key provinces for supply chain expansion include Guangdong, Jiangsu, and Shandong, while regions like Sichuan and Fujian present untapped market opportunities [3] Group 4: Product Focus and Cost Management - The raw material drug segment will focus on high-margin products such as enrofloxacin and tobramycin, while enhancing production efficiency and reducing unit costs [3] - The company is monitoring the impact of the declining pig cycle on its livestock formulation business, maintaining profitability through comprehensive solutions for poultry clients [4] Group 5: Synthetic Biology Project - The synthetic biology project, initiated in 2025 with a total investment of 680 million yuan, aims to establish a demonstration project for the industrialization of microbial protein [3] - The project is on track, with equipment commissioning and trial production expected to commence by the end of 2026 [3]

Market Overview - The animal health sector increased by 3.21% on January 19, with Huisheng Biological leading the gains [1] - The Shanghai Composite Index closed at 4114.0, up 0.29%, while the Shenzhen Component Index closed at 14294.05, up 0.09% [1] Stock Performance - Huisheng Biological (300871) closed at 28.16, up 8.18% with a trading volume of 331,800 shares [1] - Zhongmu Co., Ltd. (600195) closed at 8.49, up 7.88% with a trading volume of 435,600 shares [1] - Other notable performers include: - Biological Co. (600201) at 18.28, up 3.80% [1] - Jinhai Biological (002688) at 6.45, up 3.53% [1] - Shunlian Biological (688098) at 9.91, up 3.23% [1] Capital Flow - The animal health sector saw a net inflow of 175 million yuan from institutional investors, while retail investors experienced a net outflow of 171 million yuan [2] - The main capital flow details include: - Huisheng Biological had a net outflow of 59.49 million yuan from institutional investors [3] - Biological Co. had a net inflow of 58.13 million yuan from institutional investors [3] - Jinhai Biological experienced a net inflow of 35.35 million yuan from institutional investors [3]

Core Viewpoint - Zhongmu Co., Ltd. experienced a stock price increase of 5.72% on January 19, reaching 8.32 CNY per share, with a trading volume of 124 million CNY and a turnover rate of 1.49%, resulting in a total market capitalization of 8.496 billion CNY [1] Company Overview - Zhongmu Co., Ltd. is located at No. 188, West Fourth Ring South Road, Fengtai District, Beijing, and was established on December 25, 1998, with its listing date on January 7, 1999 [1] - The company's main business involves animal health products, including vaccines, diagnostic liquids, and veterinary drugs, as well as animal nutrition products such as feed raw materials, feed additives, and premixed feeds [1] - The revenue composition of the main business is as follows: chemical drugs 35.78%, trade 27.87%, feed 19.21%, biological products 16.10%, and others 1.04% [1] Shareholder Information - Among the top ten circulating shareholders of Zhongmu Co., Ltd., a fund under Southern Fund holds a position. The Southern CSI 1000 ETF (512100) reduced its holdings by 74,000 shares in the third quarter, now holding 4.6728 million shares, which accounts for 0.46% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a current scale of 76.63 billion CNY. Year-to-date returns are 8.41%, ranking 1574 out of 5579 in its category; over the past year, returns are 43.88%, ranking 1725 out of 4225; and since inception, returns are 23.98% [2] - The fund manager of Southern CSI 1000 ETF (512100) is Cui Lei, who has a cumulative tenure of 7 years and 75 days, managing total fund assets of 122.76 billion CNY, with the best fund return during the tenure being 247.63% and the worst being -15.93% [2]